Literature DB >> 15545274

Modeling of Galpha(s) and Galpha(i) regulation of human type V and VI adenylyl cyclase.

Misty Chen-Goodspeed1, Abolanle N Lukan, Carmen W Dessauer.   

Abstract

We examined the kinetics of Galpha(s) and Galpha(i) regulation of human type V and type VI adenylyl cyclase (AC V and AC VI) in order to better model interactions between AC and its regulators. Activation of AC VI by Galpha(s) displayed classical Michaelis-Menten kinetics, whereas AC V activation by Galpha(s) was cooperative with a Hill coefficient of 1.4. The basal activity of human AC V, but not that of AC VI, was inhibited by Galpha(i). Both enzymes showed greater inhibition by Galpha(i) at low Galpha(s) concentrations; however, human AC V was activated by Galpha(i) at high Galpha(s) concentrations. Neither regulator had an effect on the K(m) for Mg-ATP. Mutations made within the Galpha(s) binding pocket of AC V (N1090D) and VI (F1078S) displayed 6- and 14-fold greater EC(50) values for Galpha(s) activation but had no effect on Galpha(i) inhibition of basal activity or K(m) for Mg-ATP. Galpha(s)-stimulated AC VI-F1078S was not significantly inhibited by Galpha(i), despite normal inhibition by Galpha(i) upon forskolin stimulation. Mechanistic models for Galpha(s) and Galpha(i) regulation of AC V and VI were derived to describe these results. Our models are consistent with previous studies, predicting a decrease in affinity of Galpha(i) in the presence of Galpha(s). For AC VI, Galpha(s) is required for inhibition but not binding by Galpha(i). For AC V, binding of two molecules of Galpha(s) and Galpha(i) to an AC dimer are required to fully describe the data. These models highlight the differences between AC V and VI and the complex interactions with two important regulators.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15545274     DOI: 10.1074/jbc.M409172200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  The A-kinase anchoring protein Yotiao facilitates complex formation between adenylyl cyclase type 9 and the IKs potassium channel in heart.

Authors:  Yong Li; Lei Chen; Robert S Kass; Carmen W Dessauer
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.157

2.  A Novel CRISPR/Cas9-Based Cellular Model to Explore Adenylyl Cyclase and cAMP Signaling.

Authors:  Monica Soto-Velasquez; Michael P Hayes; Aktan Alpsoy; Emily C Dykhuizen; Val J Watts
Journal:  Mol Pharmacol       Date:  2018-06-27       Impact factor: 4.436

3.  N terminus of type 5 adenylyl cyclase scaffolds Gs heterotrimer.

Authors:  Rachna Sadana; Nathan Dascal; Carmen W Dessauer
Journal:  Mol Pharmacol       Date:  2009-09-25       Impact factor: 4.436

Review 4.  Cyclic AMP synthesis and hydrolysis in the normal and failing heart.

Authors:  Aziz Guellich; Hind Mehel; Rodolphe Fischmeister
Journal:  Pflugers Arch       Date:  2014-04-24       Impact factor: 3.657

5.  Functional characterization of AC5 gain-of-function variants: Impact on the molecular basis of ADCY5-related dyskinesia.

Authors:  T B Doyle; M P Hayes; D H Chen; W H Raskind; V J Watts
Journal:  Biochem Pharmacol       Date:  2019-02-14       Impact factor: 5.858

6.  A compartmentalized mathematical model of the β1-adrenergic signaling system in mouse ventricular myocytes.

Authors:  Vladimir E Bondarenko
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

Review 7.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

8.  Beneficial effects of adenylyl cyclase type 6 (AC6) expression persist using a catalytically inactive AC6 mutant.

Authors:  Mei Hua Gao; Tong Tang; Ngai Chin Lai; Atsushi Miyanohara; Tracy Guo; Rouying Tang; Amy L Firth; Jason X Yuan; H Kirk Hammond
Journal:  Mol Pharmacol       Date:  2010-12-02       Impact factor: 4.436

9.  Isoform selectivity of adenylyl cyclase inhibitors: characterization of known and novel compounds.

Authors:  Cameron S Brand; Harrison J Hocker; Alemayehu A Gorfe; Claudio N Cavasotto; Carmen W Dessauer
Journal:  J Pharmacol Exp Ther       Date:  2013-09-04       Impact factor: 4.030

10.  Activation of PH-domain leucine-rich protein phosphatase 2 (PHLPP2) by agonist stimulation in cardiac myocytes expressing adenylyl cyclase type 6.

Authors:  Mei Hua Gao; Atsushi Miyanohara; James R Feramisco; Tong Tang
Journal:  Biochem Biophys Res Commun       Date:  2009-06-26       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.